SCHEMBL684394

SCHEMBL684394

CCN1CCN(S(C)(=O)=O)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CYP2D6 P10635 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PTGS2 P35354 1/20 0.41
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HTT P42858 1/20 0.40
KDM1A O60341 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8420371 0.91 POLB (0.40) POLBKMT2ATDP1CYP2D6SMN1; SMN2
Acetic Acid SCHEMBL7990358 0.89 MAPT (0.45) POLBKMT2ATDP1ALDH1A1HTT
SCHEMBL8442784 0.82 KMT2A (0.51) POLBKMT2ACYP2D6ALDH1A1NPSR1
SCHEMBL10262951 0.81 MEN1 (0.46) KMT2ATDP1CYP2D6SMN1; SMN2ALDH1A1
SCHEMBL737197 0.81
SCHEMBL4778694 0.81 LMNA (0.50) KMT2ATDP1CYP2D6SMN1; SMN2ALDH1A1
SCHEMBL20840303 0.81 LMNA (0.50) KMT2ATDP1CYP2D6SMN1; SMN2ALDH1A1
SCHEMBL15871711 0.81 CYP2D6 (0.66) KMT2ACYP2D6SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL11919056 0.80 SMN1; SMN2 (0.60) POLBKMT2ATDP1SMN1; SMN2ALDH1A1
SCHEMBL7904548 0.80 KMT2A (0.46) POLBKMT2ACYP2D6SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
US-RE50030-E1 Methods to treat lymphoplasmacytic lymphoma DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-07-02 US disclosed
US-20230295153-A1 3-((8-((1H-PYRAZOL-4-YL)AMINO)IMIDAZO[1,2-A]PYRIDIN-3-YL)ETHINYL)-N-PHENYLBENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-09-21 US disclosed
US-20230295153-A1 3-((8-((1H-PYRAZOL-4-YL)AMINO)IMIDAZO[1,2-A]PYRIDIN-3-YL)ETHINYL)-N-PHENYLBENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-09-21 US disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
US-20230167100-A1 QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 NOVARTIS AG (CH) 2023-06-01 US disclosed
WO-2023091707-A1 BICYCLIC INHIBITORS OF JAK AND METHODS OF USE THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-05-25 WO disclosed
US-20230071620-A1 PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-03-09 US disclosed
US-20230069174-A1 NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-03-02 US disclosed
WO-2022269508-A1 PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN NOVARTIS AG (CH) 2022-12-29 WO disclosed
WO-2008008912-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. (US) 2008-01-17 WO disclosed
WO-2008008907-A2 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. (US) 2008-01-17 WO disclosed
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
US-20070275964-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER, INC. 2007-11-29 US disclosed
US-20070265260-A1 Quinazoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-11-15 US disclosed
US-7294629-B2 Quinazoline derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-11-13 US disclosed
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US disclosed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
US-20040157839-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157839-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 POLB 4653/4885KMT2A 3816/4885TDP1 4721/4885
US-20230167100-A1 QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 EZH2, BMI1, SUZ12 POLB 2473/4885KMT2A 25/4885TDP1 4127/4885
US-20230071620-A1 PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS CFD, TFPI, CFH POLB 2864/4885KMT2A 4702/4885TDP1 4456/4885
US-20230069174-A1 NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF ENPP2, NMT2, NMT1 POLB 3863/4885KMT2A 2849/4885TDP1 954/4885
US-20070060573-A1 Acyltryptophanols FSHR, NPY1R, NPY2R POLB 4403/4885KMT2A 916/4885TDP1 1811/4885
US-20230295153-A1 3-((8-((1H-PYRAZOL-4-YL)AMINO)IMIDAZO[1,2-A]PYRIDIN-3-YL)ETHINYL)-N-PHENYLBENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER ABL1, ABL2, CDKN1A POLB 3088/4885KMT2A 487/4885TDP1 1875/4885
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF KDM1A, TET1, KDM3A POLB 1185/4885KMT2A 43/4885TDP1 275/4885
US-20070275964-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, GPR18 POLB 4664/4885KMT2A 3785/4885TDP1 4779/4885
US-20070265260-A1 Quinazoline derivatives TYK2, ROR1, JAK1 POLB 1996/4885KMT2A 3039/4885TDP1 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.